Cardiotoxicity Assessment of Drugs Using Human iPS Cell-Derived Cardiomyocytes: Toward Proarrhythmic Risk and Cardio-Oncology

Author(s): Ayano Satsuka, Yasunari Kanda*

Journal Name: Current Pharmaceutical Biotechnology

Volume 21 , Issue 9 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Growing evidence suggests that Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs) can be used as a new human cell-based platform to assess cardiac toxicity/safety during drug development. Cardiotoxicity assessment is highly challenging due to species differences and various toxicities, such as electrophysiological and contractile toxicities, which can result in proarrhythmia and heart failure. To explore proarrhythmic risk, the Multi-Electrode Array (MEA) platform is widely used to assess QT-interval prolongation and the proarrhythmic potential of drug candidates using hiPSC-CMs. Several consortiums, including the Comprehensive in vitro Proarrhythmia Assay (CiPA) and the Japanese iPS Cardiac Safety Assessment (JiCSA), have demonstrated the applicability of hiPSC-CMs/MEA for assessing the torsadogenic potential of drug candidates. Additionally, contractility is a key safety issue in drug development, and efforts have been undertaken to measure contractility by a variety of imaging-based methods using iPS-CMs. Therefore, hiPSC-CMs might represent a standard testing tool for evaluating the proarrhythmic and contractile potentials. This review provides new insights into the practical application of hiPSC-CMs in early or late-stage nonclinical testing during drug development.

Keywords: Cardiac safety, human iPS cells, multi-electrode array, proarrhythmia, contractility, standardization.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 21
ISSUE: 9
Year: 2020
Page: [765 - 772]
Pages: 8
DOI: 10.2174/1389201020666190628143345
Price: $65

Article Metrics

PDF: 22